LI-RADS plans makeover for liver cancer diagnoses
The American College of Radiology's routine announcement about a new committee for liver imaging reporting is the starting point for an ambitious plan to reinvent how radiologists diagnose and evaluate hepatocellular carcinoma.
The American College of Radiology's routine announcement about a new committee for liver imaging reporting is the starting point for an ambitious plan to reinvent how radiologists diagnose and evaluate hepatocellular carcinoma.
The Liver Imaging Reporting and Data System (LI-RADS) addresses frequent complaints from referring physicians about inconsistencies in the interpretation of MR and CT for HCC, according to Dr. Claude Sirlin, LI-RADS committee chair.
The ACR LI-RADS program was announced in October 2009 to discourage other, independent efforts to address the HCC lexicon program, Sirlin said.
Radiologists should not expect to see the LI-RADS lexicon until at least late 2010. Its volunteer committees need time to design and test major components, including:
• a lexicon of terms to describe number, size, shape, and location of hepatic lesions;
• a standard reporting format for MRI and CT; and
• a standardized method for estimating the probability of malignancy based on a lesion’s imaging features.
In the long run, standardization will permit the ACR or other designated groups to download individual reports into a computerized national registry of multi-institutional HCC image reporting experience, Sirlin said. Database evaluations could eventually be used to assess the effect of image interpretation on clinical decision-making and patient outcomes.
FDA Clears Virtually Helium-Free 1.5T MRI System from Siemens Healthineers
June 26th 2025Offering a cost- and resource-saving DryCool magnet technology, the Magnetom Flow.Ace MRI system reportedly requires 0.7 liters of liquid helium for cooling over the lifetime of the device in contrast to over 1,000 liters commonly utilized with conventional MRI platforms.
SNMMI: Botox May Facilitate Relief from Dry Mouth Side Effect of PSMA-Targeted Radiopharmaceuticals
June 25th 2025For patients being treated with radiopharmaceutical agents for metastatic prostate cancer, the combination of botulinum toxin and an anti-nausea patch led to a 30 percent reduction in PSMA uptake in the salivary glands, according to preliminary research findings presented at the SNMMI conference.
SNMMI: Can 18F-Fluciclovine PET/CT Bolster Detection of PCa Recurrence in the Prostate Bed?
June 24th 2025In an ongoing prospective study of patients with biochemical recurrence of PCa and an initial negative PSMA PET/CT, preliminary findings revealed positive 18F-fluciclovine PET/CT scans in over 54 percent of the cohort, according to a recent poster presentation at the SNMMI conference.
